Log In
Print
BCIQ
Print
Print this Print this
 

RPC4046

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionRecombinant humanized mAb against interleukin-13 (IL-13)
Molecular Target Interleukin-13 (IL-13)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationEosinophilic esophagitis
Indication DetailsTreat eosinophilic esophagitis (EoE)
Regulatory Designation U.S. - Orphan Drug (Treat eosinophilic esophagitis (EoE))
Partner Receptos Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$7,321.0M

$7,321.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today